Related Experiment Video

Updated: Aug 19, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

MET alterations in NSCLC-Current Perspectives and Future Challenges

Jordi Remon1, Lizza E L Hendriks2, Giannis Mountzios3

  • 1Department of Cancer Medicine, Gustave Roussy, Villejuif, France.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|November 28, 2022
PubMed

Insights

MET alterations drive non-small cell lung cancer (NSCLC). This review covers MET-targeted therapies, diagnostic methods, and their role alongside immunotherapy for MET-dysregulated NSCLC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Translational Medicine

Background:

  • Non-small cell lung cancer (NSCLC) treatment has advanced with oncogene-driven therapies.
  • MET dysregulation, including MET exon 14 skipping mutations and amplifications, is a key resistance mechanism in NSCLC.
  • Targeted therapies offer improved outcomes for specific NSCLC subtypes.

Purpose of the Study:

  • To review the role of MET as an oncogenic driver in NSCLC.
  • To discuss diagnostic methods for MET alterations (exon 14 skipping, amplification, overexpression).
  • To summarize current and emerging targeted therapies for MET-altered NSCLC and their integration with immunotherapy.

Main Methods:

  • Narrative review of existing literature.
  • Analysis of clinical trial data for MET-targeted therapies.
  • Perspective on immunotherapy in MET-dysregulated NSCLC.

Main Results:

  • Several anti-MET targeted therapies are approved for MET exon 14 skipping mutations, with more in development.
  • MET alterations are common bypass mechanisms in oncogene-addicted NSCLC.
  • Data on immunotherapy for MET-dysregulated NSCLC is being evaluated.

Conclusions:

  • Targeted therapies are crucial for MET-altered NSCLC.
  • Accurate diagnostic testing is essential for patient selection.
  • Further research is needed to optimize treatment strategies and overcome resistance.
Keywords:
AmivantamabCapmatinibMET amplifiedMET exon 14Non–small cell lung cancerTepotinib

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.1K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K